# Immatics (IMTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IMTX
## Company Profile
- Ticker: IMTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Germany with major U
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 9.77 USD
- Market cap: 1372198536.4399998 USD
- Last updated: 2026-08-05
## Business Overview
### TCR-Based Solid Tumor Immunotherapy
Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules.
### PRAME Franchise
The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers.
### Anzu-cel
Anzu-cel is an autologous PRAME-directed cell therapy in the pivotal Phase 3 SUPRAME study and is intended to become Immatics’ first commercial product.
### Next-Generation Programs
IMA203CD8 adds engineered CD8 signaling, while IMA402 is a PRAME TCR bispecific being studied alone and with checkpoint inhibition.
### Target Discovery and Manufacturing
Immatics integrates immunopeptidomics-based target discovery with TCR engineering, cell manufacturing, and bispecific development to build multiple therapies against the same cancer target.
## Why The Stock Is Moving

As of Aug 5, 2026, IMTX closed up 4.16% at $9.77. No new same-company headline was identified in the current news window.

## Future Catalysts

- Interim and final analyses from the Phase 3 SUPRAME study are expected to be triggered during 2026.
- Phase 1 IMA203CD8 data in gynecologic cancers are scheduled for presentation at ASCO 2026.
- Phase 1b data for IMA402, including initial checkpoint-inhibitor combination data, are expected in the second half of 2026.
- A potential commercial launch of anzu-cel is planned for 2027.

## Recent News
- 2026-07-17 14:25 EST — [Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026](https://biopharmsignal.com/news/IMTX/immatics-announces-upcoming-presentations-across-its-prame-franchise-at-esmo-con-da7395b0) — Source: Immatics
- 2026-06-01 12:00 EST — [Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-and-response-dynamics-of-anzu-cel-prame-cell-therapy-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-31 13:00 EST — [Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer](https://biopharmsignal.com/news/IMTX/immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-development-of-ima401-ima402-combination-in-lung-cancer) — Source: Immatics
- 2026-05-30 12:00 EST — [Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-12 11:00 EST — [Immatics Announces First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/IMTX/immatics-announces-first-quarter-2026-financial-results-and-business-update) — Source: Immatics